Cardio Diagnostics Holdings, Inc.

NasdaqCM CDIO

Cardio Diagnostics Holdings, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 35.69 K

Cardio Diagnostics Holdings, Inc. Revenue is USD 35.69 K for the Trailing 12 Months (TTM) ending September 30, 2024, a 180.90% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Cardio Diagnostics Holdings, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 12.71 K, a 1,310.10% change year over year.
Cardio Diagnostics Holdings, Inc. Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 901.00.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqCM: CDIO

Cardio Diagnostics Holdings, Inc.

CEO	Dr. Meeshanthini V. Dogan Ph.D.
IPO Date	Jan. 14, 2022
Location	United States
Headquarters	400 N Aberdeen St
Employees	7
Sector	Health Care
Industries Clinical Trials Biotechnology

Description

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

Key trends

Past 5 years